A Novel Deleterious Variant and a Founder Effect in Four New Families of MBD4 ‐Associated Neoplasia Syndrome Recruited Over a Period of 20 Years
Clinical Genetics · 2026
DOI: 10.1111/cge.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Inês Querido und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics Group, IPO Porto Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)…. Hauptthemen laut MEDLINE: Founder Effect, Endodeoxyribonucleases, Adenomatous Polyposis Coli, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia, Liga Portuguesa Contra o Cancro, Instituto Português de Oncologia do Porto.
Abstract (Originalsprache)
DNA glycosylases play a crucial role in DNA repair mediated by the base excision repair (BER) pathway, and alterations in these enzymes have been associated with hereditary cancer predisposition. Recently, germline biallelic loss‐of‐function variants in MBD4 were shown to be responsible for a novel autosomal recessive multi‐tumor predisposition syndrome, provisionally denominated as MBD4 ‐associated neoplasia syndrome and characterized by the association of adenomatous polyposis, colorectal cancer, and acute myeloid leukemia (AML). Here, we studied the MBD4 gene in five individuals from four families affected by adenomatous polyposis and AML, who had been referred for genetic counselling at a single institution over a period of approximately 20 years. All patients with this phenotype presented homozygous deleterious germline variants in MBD4 , of which one is a founder variant recurrent in three of the families, and another variant has not been previously described in the literature. Our work allowed a molecular diagnosis for these families and significantly contributes to expanding the knowledge about this emerging syndrome caused by MBD4 constitutional deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
- Department of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
- Department of Pathological, Cytological and Thanatological Anatomy, School of Health, Polytechnic Institute of Porto, Porto, Portugal.
- Department of Medical Genetics, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
- Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
- European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal.
Förderung
- Fundação para a Ciência e a Tecnologia
- Liga Portuguesa Contra o Cancro
- Instituto Português de Oncologia do Porto
- European Reference Network on Genetic Tumour Risk Syndromes
Zitieren
APA
Querido, I., Pinto, C., Arinto, P., Brandão, A., Santos, C., Pinheiro, M., Guerra, J., Silva, J., Peixoto, A., & Teixeira, M. R. (2026). A Novel Deleterious Variant and a Founder Effect in Four New Families of MBD4 ‐Associated Neoplasia Syndrome Recruited Over a Period of 20 Years. Clinical Genetics. https://doi.org/10.1111/cge.70014
Vancouver
Querido I, Pinto C, Arinto P, Brandão A, Santos C, Pinheiro M, et al. A Novel Deleterious Variant and a Founder Effect in Four New Families of MBD4 ‐Associated Neoplasia Syndrome Recruited Over a Period of 20 Years. Clinical Genetics. 2026. doi:10.1111/cge.70014
BibTeX
@article{Querido2026,
author = {Querido, Inês and Pinto, Carla and Arinto, Patrícia and Brandão, Andreia and Santos, Catarina and Pinheiro, Manuela and Guerra, Joana and Silva, João and Peixoto, Ana and Teixeira, Manuel R},
title = {A Novel Deleterious Variant and a Founder Effect in Four New Families of MBD4 ‐Associated Neoplasia Syndrome Recruited Over a Period of 20 Years},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70014}
}
EUVIMED